Skip to main content

Alpha-1-Proteinase Inhibitor (Human) Medicare Part D Coverage

Brand name: Aralast NP NP
Dosage form
KIT
17%
of Medicare Part D plans
cover Alpha-1-Proteinase Inhibitor (Human)
959 of 5,530 plans
4.6
Avg. formulary tier
$0.00
Median 30-day copay
$0.00–$0.00
Copay range

Formulary Tier Distribution

How Medicare Part D plans classify Alpha-1-Proteinase Inhibitor (Human). Lower tiers = lower copays.

Tier 1 - Preferred Generic 3%
31 plans • avg $0.00/mo
Tier 2 - Generic 0%
2 plans • avg $0.00/mo
Tier 3 - Preferred Brand 12%
115 plans • avg $17.61/mo
Tier 4 - Non-Preferred Drug 0%
3 plans • avg $0.00/mo
Tier 5 - Specialty 84%
801 plans • avg $0.00/mo
Tier 6 - Select Care 1%
7 plans • avg $0.00/mo

Find the cheapest plan for Alpha-1-Proteinase Inhibitor (Human)

Enter your ZIP code to compare every plan in your area side-by-side.

Compare Plans for Alpha-1-Proteinase Inhibitor (Human) →

Get Alpha-1-Proteinase Inhibitor (Human) Delivered to Your Door

Compare prices and get discounts from trusted online pharmacies

DrugCovered may earn commissions from pharmacy purchases. Prices and availability vary. Always consult your doctor before starting or changing medications.

Alpha-1-Proteinase Inhibitor (Human) Medicare Coverage by State

Coverage rates and average costs vary significantly by state. Click a state to see the specific plans available there.

Frequently Asked Questions about Alpha-1-Proteinase Inhibitor (Human)

17% of Medicare Part D plans cover Alpha-1-Proteinase Inhibitor (Human). It is most commonly placed on Tier 5. Coverage varies by plan and geographic area.

The median 30-day copay for Alpha-1-Proteinase Inhibitor (Human) on Medicare Part D is $0.00 at a preferred pharmacy. Costs range from $0.00 to $0.00 depending on the plan.

Alpha-1-Proteinase Inhibitor (Human) is placed on Tier 5 by most Medicare Part D plans. Lower tier numbers generally mean lower copays.

0% of plans require prior authorization for Alpha-1-Proteinase Inhibitor (Human). Prior authorization means your doctor must confirm the drug is medically necessary before the plan will cover it.

Coverage statistics based on CMS formulary data for plan year 2026. Data updated regularly. Methodology →